Chonluten (also known as Tripeptide T-34 or EDG) is a synthetic short peptide bioregulator consisting of three amino acids in the sequence L-Glutamic acid, L-Aspartic acid, and L-Glycine. Developed as part of the Khavinson peptide framework, it is primarily researched and marketed for its targeted biological activity on the respiratory system and gastrointestinal mucosa.
Primary Characteristics & Research FocusTissue Specificity: It acts as an organ-specific cytogenetic regulator, primarily targeting lung tissues, bronchial mucosa, and respiratory epithelium.
Mechanism of Action: Research from platforms like PubMed indicates that Chonluten interacts with cellular mechanisms to modulate gene expression, protein biosynthesis, and oxidative stress responses.
Anti-Inflammatory Properties: In vitro laboratory research suggests it assists in inhibiting pro-inflammatory cytokine production (such as TNF-Ξ± and IL-6), promoting cellular regeneration over tissue degradation.
Investigational Uses: Because it stabilizes mucosal integrity, it is evaluated in experimental frameworks for potential support in chronic conditions like COPD, asthma, and gastritis.